Seoul: Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, announced the launch of its biosimilar product for Stelara, an autoimmune disease treatment, in the United States.
According to Yonhap News Agency, Pyzchiva, which treats conditions such as plaque psoriasis, Crohn's disease, active psoriatic arthritis, and ulcerative colitis, marks Samsung Bioepis' fifth biosimilar product to enter the U.S. market. The company revealed in a press release that the launch was executed through its local marketing partner, Sandoz.
The global market for Stelara is valued at approximately US$10.3 billion, with the United States contributing to two-thirds of the global sales. Prior to this U.S. launch, Samsung Bioepis had already introduced the biosimilar drug in Europe and South Korea last year.